SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
April 20, 2001
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|(State or other Jurisdiction||(Commission File Number)||(I.R.S. Employer|
|of Incorporation)||Identification No.)|
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (847) 937-6100
Attached as Exhibit 99.1 and incorporated herein by this reference is a press release by Abbott Laboratories announcing an adjustment in litigation reserves.
|99.1||Press Release, dated April 20, 2001|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
/s/ THOMAS C. FREYMAN
Thomas C. Freyman
Senior Vice President, Finance
and Chief Financial Officer
Date: April 20, 2001
Health Care Worldwide
Abbott Park, Illinois 60064
|For Immediate Release
ABBOTT LABORATORIES ADJUSTS LITIGATION RESERVES
ABBOTT PARK, Ill., April 20, 2001Abbott Laboratories today announced an adjustment in litigation reserves to reflect recent developments related to the U.S. Department of Justice investigation into the marketing and sales practices of TAP Pharmaceutical Products Inc. for Lupron®. TAP Pharmaceutical Products Inc. is a 50/50 joint venture between Abbott and Takeda Chemical Industries, Ltd.
Discussions between TAP and the Department of Justice are ongoing. The government's inquiry has focused solely on marketing and sales practices, and does not involve the safety and efficacy of Lupron.
This one-time adjustment in the litigation reserves will cause an adjustment to previously announced first quarter results, as reflected in the attached table. While it is not feasible to predict the outcome of this proceeding with certainty, no material impact on operations, or additional one-time charges are expected.
This adjustment to litigation reserves does not impact previously provided diluted earnings-per-share guidance for ongoing results for the second quarter, and for the full-year 2001.
Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries. In 2000, the company's sales and net earnings were $13.7 billion and $2.8 billion, respectively, with diluted earnings per share of $1.78.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Private Securities Litigation Reform Act of 1995
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Exhibit 99.1 of our 2000 Form 10-K and in our periodic reports on Form 10-Q and Form 8-K, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.
Abbott Laboratories and Subsidiaries
Consolidated Statement of Earnings
Three Months Ended March 31, 2001
||As Previously Reported
|Cost of products sold||1,643,318,000||||1,643,318,000|
|Research & development||318,280,000||||318,280,000|
|Acquired In-process R&D (1)||1,015,000,000||||1,015,000,000|
|Selling, general & administrative||747,013,000||||747,013,000|
|Net interest expense||26,721,000||||26,721,000|
|Net foreign exchange loss||9,070,000||||9,070,000|
|(Income) from TAP Pharmaceutical Products Inc. joint venture||(150,057,000||)||344,000,000||(3)||193,943,000|
|Other (income)/expense, net||(4,781,000||)||||(4,781,000||)|
|Earnings Before Taxes||(44,684,000||)||(344,000,000||)||(388,684,000||)|
|Taxes on earnings (1)(2)||(140,991,000||)||(24,080,000||)||(165,071,000||)|
|Net Earnings Excluding Acquired In-Process R&D And Other One-Time Charges||$||734,877,000||||$||734,877,000|
|Diluted Earnings Per Common Share:|
|Excluding acquired In-process R&D and other one-time charges||$||0.47||||$||0.47|
|Acquired in-process R&D and other one-time charges (4)||(0.41||)||||(0.41||)|
|Total After One-Time Charges As Previously Reported||0.06||||0.06|
|One-Time adjustment to Income from TAP joint venture||||(0.20||)||(0.20||)(5)|
|Total After Adjustment to income from TAP Joint Venture||$||0.06||$||(0.20||)||$||(0.14||)(5)|
|Average Number of Diluted Common Shares Outstanding||1,565,416,000||1,565,416,000|
position, ongoing cash flow or the results of ongoing operations. The one-time impact on cash flow upon resolution would occur in a future period.